Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318

Vandria has announced the first-in-human data for its Alzheimer’s candidate, VNA-318. This marks a significant milestone as VNA-318 is the first mitophagy-based therapeutic approach for Alzheimer’s disease to reach clinical trials. Mitophagy, a process that involves the removal of damaged mitochondria from cells, is being explored as a potential pathway to address neurodegenerative diseases such as Alzheimer’s.

The company has developed VNA-318 using its proprietary technology platform and aims to target mitochondrial dysfunction, which is believed to play a role in the progression of Alzheimer’s disease. The release of this initial human data represents an important step in evaluating the safety and efficacy of this novel therapeutic approach. Further details regarding the trial outcomes or next steps have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: The formatted date is: December 2, 2025

Related posts:

Measles Outbreak in the United States: A Resurgence of a Vaccine-Preventable Disease Republican Senators Explore Medicare Advantage Upcoding Reforms to Offset Tax Cut Costs Congress Advances Bill to Authorize FDA Oversight of Digital Prescription Information Transition Biodegradable Cesium Nanosalts Developed to Induce Pyroptosis and Disrupt Tumor Metabolism

Author

GOAI